Advertisement

Autologous stem cell therapy for peripheral arterial disease

Meta-analysis and systematic review of the literature
  • Gian Paolo Fadini
    Correspondence
    Corresponding author at: Dipartimento di Medicina Clinica e Sperimentale, Divisione di Malattie del Metabolismo, Policlinico Universitario, via Giustiniani, 2, 35100, Padova, Italy. Tel.: +39 049 8212185; fax: +39 049 8212184.
    Affiliations
    Department of Clinical and Experimental Medicine, University of Padova, Medical School, Padova, Italy
    Search for articles by this author
  • Carlo Agostini
    Affiliations
    Department of Clinical and Experimental Medicine, University of Padova, Medical School, Padova, Italy
    Search for articles by this author
  • Angelo Avogaro
    Affiliations
    Department of Clinical and Experimental Medicine, University of Padova, Medical School, Padova, Italy
    Search for articles by this author

      Abstract

      Background

      Peripheral arterial disease (PAD) is a common cause of disability and mortality. Up to one third of patients are not susceptible to traditional revascularization and may benefit from stem cell therapies.

      Objective

      In this meta-analysis, we sought to determine whether autologous cell therapy is effective in the treatment of PAD.

      Methods

      We searched the English literature in Medline, Excerpta Medica and the Cochrane database for trials of autologous cell therapy in patients with PAD published before 31 January 2009. We included controlled and non-controlled, randomized and non-randomized trials using autologous bone marrow or granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood cells to treat PAD. We also collected data from trials of G-CSF monotherapy, as a control treatment.

      Results

      In a meta-analysis of 37 trials, autologous cell therapy was effective in improving surrogate indexes of ischemia, subjective symptoms and hard endpoints (ulcer healing and amputation). On the contrary, G-CSF monotherapy was not associated with significant improvement in the same endpoints. Patients with thromboangiitis obliterans showed some larger benefits than patients with atherosclerotic PAD. The intramuscular route of administration and the use of bone marrow cells seemed somehow more effective than intrarterial administration and the use of mobilized peripheral blood cells. The procedures were well tolerated and generally safe.

      Conclusion

      This meta-analysis indicates that intramuscular autologous bone marrow cell therapy is a feasible, relatively safe and potentially effective therapeutic strategy for PAD patients, who are not candidate for traditional revascularization. Larger, placebo-controlled, randomized multicenter trials need to be planned and conducted to confirm these findings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hirsch A.T.
        • Criqui M.H.
        • Treat-Jacobson D.
        • et al.
        Peripheral arterial disease detection, awareness, and treatment in primary care.
        JAMA. 2001; 286: 1317-1324
        • Olin J.W.
        Thromboangiitis obliterans (Buerger's disease).
        N Engl J Med. 2000; 343: 864-869
        • Hankey G.J.
        • Norman P.E.
        • Eikelboom J.W.
        Medical treatment of peripheral arterial disease.
        JAMA. 2006; 295: 547-553
        • Asahara T.
        • Murohara T.
        • Sullivan A.
        • et al.
        Isolation of putative progenitor endothelial cells for angiogenesis.
        Science. 1997; 275: 964-967
        • Fadini G.P.
        • Agostini C.
        • Sartore S.
        • Avogaro A.
        Endothelial progenitor cells in the natural history of atherosclerosis.
        Atherosclerosis. 2007; 194: 46-54
        • Fadini G.P.
        • Miorin M.
        • Facco M.
        • et al.
        Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus.
        J Am Coll Cardiol. 2005; 45: 1449-1457
        • Fadini G.P.
        • Sartore S.
        • Albiero M.
        • et al.
        Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy.
        Arterioscler Thromb Vasc Biol. 2006; 26: 2140-2146
        • Fadini G.P.
        • Sartore S.
        • Agostini C.
        • Avogaro A.
        Significance of endothelial progenitor cells in subjects with diabetes.
        Diabetes Care. 2007; 30: 1305-1313
        • Werner N.
        • Nickenig G.
        Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?.
        Arterioscler Thromb Vasc Biol. 2006; 26: 257-266
        • Lipinski M.J.
        • Biondi-Zoccai G.G.
        • Abbate A.
        • et al.
        Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials.
        J Am Coll Cardiol. 2007; 50: 1761-1767
        • Moher D.
        • Cook D.J.
        • Eastwood S.
        • et al.
        Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.
        Lancet. 1999; 354: 1896-1900
        • Stroup D.F.
        • Berlin J.A.
        • Morton S.C.
        • et al.
        Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
        JAMA. 2000; 283: 2008-2012
        • Cleophas T.J.
        • Zwinderman A.H.
        Meta-analysis.
        Circulation. 2007; 115: 2870-2875
        • Kawamura A.
        • Horie T.
        • Tsuda I.
        • et al.
        Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation.
        Ther Apher Dial. 2005; 9: 59-63
        • Kirana S.
        • Stratmann B.
        • Lammers D.
        • et al.
        Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs.
        Int J Clin Pract. 2007; 61: 690-692
        • Sugihara S.
        • Yamamoto Y.
        • Matsubara K.
        • et al.
        Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans.
        Heart Vessels. 2006; 21: 258-262
        • Umemura T.
        • Nishioka K.
        • Igarashi A.
        • et al.
        Autologous bone marrow mononuclear cell implantation induces angiogenesis and bone regeneration in a patient with compartment syndrome.
        Circ J. 2006; 70: 1362-1364
        • Ozawa T.
        • Kato K.
        • Sanada H.
        • et al.
        Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia—a case report.
        Angiology. 2006; 57: 235-239
        • Kim S.W.
        • Han H.
        • Chae G.T.
        • et al.
        Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model.
        Stem Cells. 2006; 24: 1620-1626
        • Kim D.I.
        • Kim M.J.
        • Joh J.H.
        • et al.
        Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease.
        Stem Cells. 2006; 24: 1194-1200
        • Van Tongeren R.B.
        • Hamming J.F.
        • Fibbe W.E.
        • et al.
        Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia.
        J Cardiovasc Surg (Torino). 2008; 49: 51-58
        • Nakayama M.
        • Asari Y.
        Angiogenesis achieved by granulocyte colony-stimulating factor in combination with bypass surgery in 2 cases of critical limb ischemia.
        Circ J. 2008; 72: 1385-1387
        • van Royen N.
        • Schirmer S.H.
        • Atasever B.
        • et al.
        START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
        Circulation. 2005; 112: 1040-1046
        • Huang P.
        • Li S.
        • Han M.
        • et al.
        Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.
        Diabetes Care. 2005; 28: 2155-2160
        • Napoli C.
        • Farzati B.
        • Sica V.
        • et al.
        Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia.
        Eur J Cardiovasc Prev Rehabil. 2008; 15: 709-718
        • Arai M.
        • Misao Y.
        • Nagai H.
        • et al.
        Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease.
        Circ J. 2006; 70: 1093-1098
        • Matoba S.
        • Tatsumi T.
        • Murohara T.
        • et al.
        Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia.
        Am Heart J. 2008; 156: 1010-1018
        • Huang P.P.
        • Yang X.F.
        • Li S.Z.
        • et al.
        Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans.
        Thromb Haemost. 2007; 98: 1335-1342
        • Hoshino J.
        • Ubara Y.
        • Hara S.
        • et al.
        Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis.
        Circ J. 2007; 71: 1193-1198
        • Hirsch A.T.
        Critical limb ischemia and stem cell research: anchoring hope with informed adverse event reporting.
        Circulation. 2006; 114: 2581-2583
        • Miyamoto K.
        • Nishigami K.
        • Nagaya N.
        • et al.
        Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans.
        Circulation. 2006; 114: 2679-2684
        • Heiss C.
        • Keymel S.
        • Niesler U.
        • et al.
        Impaired progenitor cell activity in age-related endothelial dysfunction.
        J Am Coll Cardiol. 2005; 45: 1441-1448
        • Fadini G.P.
        • de Kreutzenberg S.V.
        • Coracina A.
        • et al.
        Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk.
        Eur Heart J. 2006; 27: 2247-2255
        • Honold J.
        • Lehmann R.
        • Heeschen C.
        • et al.
        Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease.
        Arterioscler Thromb Vasc Biol. 2006; 26: 2238-2243
        • Heil M.
        • Ziegelhoeffer T.
        • Mees B.
        • Schaper W.
        A different outlook on the role of bone marrow stem cells in vascular growth. bone marrow delivers software not hardware.
        Circ Res. 2004; 94: 573-574